THE TOOKIE VEST MAKING # ALIFEMORENORMAL
SMITH & NEPHEW PARTNERS WITH THE UNIVERSITY OF HULL
THE TOOKIE VEST MAKING # ALIFEMORENORMAL
Medilink member Tookie Limited, based at the Innovation Hub at Liverpool Alder Hey Children’ s Hospital, is a team of medical innovators focused upon identifying and responding to unmet needs that will enable patients and their families to lead # ALifeMoreNormal.
Over 10,000 children are being treated for cancer in the UK and approximately £ 19 million is spent each year on treating central line infection. A large proportion of this could be avoided with one simple solution – a Tookie Vest.
The Tookie Vest for Oncology is a CE marked medical device for children receiving cancer treatment through Central Venous Catheter( CVC) lines.
The vest is designed to maintain integrity of the central line, to prevent inadvertent fall outs by holding the central line in place inside a pouch attached to the vest. Additionally, the Tookie Smart Vest features embedded textile biosensors that capture and send vital patient information via Wi-Fi to a smart phone for enhanced patient self-care and monitoring in the home.
Mr Ross J Craige, Consultant Paediatric Surgeon, Royal Manchester Children’ s Hospital said:“ I see firsthand the concerns that parents have around care and security of
their child’ s central line and also the implications of premature line removal. The Tookie Vest aims to give both actual line security and also peace of mind to families, something that we have been waiting for in central line care.”
Tookie are adapting the Tookie Vest, for uses in other clinical areas. The Tookie Vest for adult renal patients undergoing Haemodialysis( HD) through a CVC has been designed with clinical and patient input from City Hospitals Sunderland NHS Trust.
The final design is currently being CE marked, and will be subject of a multicentre study led by City Hospitals Sunderland NHS Trust.
In July 2017, a focus group met to investigate and design through PPI, the Tookie Vest for Paediatric Renal patients. The group is being led by Dr Yincent Tse and Dr Heather Lambert, both Consultant Paediatric Nephrologist Surgeon’ s at the Great Northern Children’ s Hospital in Newcastle.
Another focus group and PPI will be held at the Sheffield Children’ s Hospital with Professor Dr. Heather Elphick as the Chief Investigator, to investigate the un-met needs of respiratory patients.
The company is also involved in developing nutrition Tookie Vests to suit patient groups’ needs to support their lines, as well as the Tookie Smart Vest, with embedded biosensor technology.
Tookie recently presented as part of an‘ Academy of Fabulous NHS Stuff’ event. The Academy was founded by Roy Lilley and is a repository which has become a social movement and is seen as the change platform for the NHS and Social Care. Tookie presented at the event alongside Mr Saeed Ahmed, Consultant Interventional Nephrologist of City Hospital Sunderland Foundation Trust and Tookie Chief Investigator for Renal.
@ TookieCo(# ALifeMoreNormal) www. tookie. co
SMITH & NEPHEW PARTNERS WITH THE UNIVERSITY OF HULL
Global medical technology business, Smith & Nephew, has announced a long-term collaboration with the University of Hull to drive research into ground-breaking methods in advanced wound care.
This partnership will be one of the world’ s largest Wound Care Research Clusters, combining world-leading academia and industry, which together will focus on developing scientific insights and innovative treatments for advanced wound care.
A co-investment of around £ 3 million was set within an established framework of five years and has created eight multi-disciplinary PhD studentships.
Smith & Nephew’ s new state-of-the-art Research & Development( R & D) centre in Hull and the University of Hull’ s £ 28m new Health Campus will support this collaboration.
Stewart McKinlay, Vice President of Research & Innovation, Smith & Nephew, said:“ There will be opportunities for students and employees to interact on a daily basis to share knowledge, best practice and support our ambitious R & D pipeline. Combine that with the scale of scientific specialities that is based here, then this partnership is a truly exciting prospect.”
9